As an alternative to the targeted therapies now commonly used in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), a novel bispecific T-cell engager called epcoritamab (Epkinly, Genmab/AbbVie) showed a high degree of activity in a study that attracted attention at the 2024 ASH Annual Meeting & Exposition (abstract 883) despite its small size.
Epcoritamab, which is already approved for the treatment of relapsed B-cell lymphomas after two lines of prior therapy, binds to CD3 on T